MCL1 and melanoma: Even in cells that rely on MCL1 for survival, such as melanoma, depletion of MCL1 or treatment with lower doses of MCL1 inhibitors lead to drastic inhibition of mTORC1 much earlier before the detection of any cellular or molecular signs of cell death and is not modulated by blocking caspase activation.